Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald

Stock analysts at Cantor Fitzgerald assumed coverage on shares of Harrow (NASDAQ:HROW - Get Free Report) in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. The brokerage set an "overweight" rating and a $76.00 price target on the stock. Cantor Fitzgerald's price target points to a potential upside of 142.27% from the company's current price.

A number of other equities research analysts have also commented on the company. William Blair initiated coverage on Harrow in a research report on Tuesday, June 10th. They set an "outperform" rating on the stock. HC Wainwright raised their price target on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. B. Riley dropped their price target on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Finally, BTIG Research began coverage on Harrow in a report on Thursday, June 12th. They set a "buy" rating and a $62.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $63.83.

Harrow Trading Down 0.9%

NASDAQ:HROW opened at $31.37 on Friday. Harrow has a 1-year low of $20.85 and a 1-year high of $59.23. The business's 50-day moving average price is $28.84 and its two-hundred day moving average price is $28.81. The company has a current ratio of 0.91, a quick ratio of 0.85 and a debt-to-equity ratio of 2.01. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -56.02 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The business had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. On average, equities analysts expect that Harrow will post -0.53 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Harrow by 89.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company's stock valued at $2,078,000 after purchasing an additional 29,262 shares in the last quarter. GAMMA Investing LLC grew its stake in Harrow by 2,401.2% in the first quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock valued at $1,670,000 after purchasing an additional 6,027 shares in the last quarter. Northern Trust Corp grew its stake in Harrow by 7.5% in the fourth quarter. Northern Trust Corp now owns 319,084 shares of the company's stock valued at $10,705,000 after purchasing an additional 22,266 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Harrow by 769.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after purchasing an additional 1,462 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Harrow by 8.4% during the 4th quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company's stock worth $2,900,000 after acquiring an additional 6,690 shares during the period. 72.76% of the stock is currently owned by institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.